Rostec announced the timing of the release of a single vaccine against COVID and influenza

The HEAD of the state corporation Sergei Chemezov plans to present the results of the developments this year. In the spring of 2021, he stated,

Rostec continues to develop its own combined vaccine against CORONAVIRUS and influenza, the first results of the work will be presented in 2022. This was stated by the head of the state corporation Sergei Chemezov, whose words are quoted by RIA Novosti.

“While we are working. <...> it is necessary to carry out all the tests so that it is safe, first of all, and effective, ”he said, noting that the research results are“ good ”, but some details have yet to be finalized.

On April 24, Chemezov announced that Rostec had developed a combined vaccine against coronavirus and influenza. Then he noted that the vaccine would be one-component, it was planned to register it before the end of 2021 or at the beginning of 2022.

In March 2021, Andrey Zagorsky, CEO of the Nacimbio holding owned by Rostec, told RBC TV that the company was working on its own covid-19 vaccine . “We are developing a covid vaccine <...>, as soon as we register, we will be the first to inform you about it,” Zagorsky said

On April 1, 2020, Rostec announced that the Ministry of HEALTH had registered a specific immunoglobulin preparation developed by Nacimbio for the treatment of COVID-19, created on the basis of the blood plasma of recovered patients.

Klishas said that compulsory vaccination does not contradict the Constitution Society

Read on RBC Pro "Golden parachutes" are a thing of the past. What will replace them What will 2022 be like: business gurus Musk, Gates, Benioff say

Other Russian institutions and companies are also working on a single vaccine against influenza and coronavirus. In particular, at the end of November, the Human Stem Cell Institute announced its intention to begin preclinical trials of its vaccine in early 2022. According to the head of the board of directors of the organization Artur Isaev, the creators of the drug are counting on its effectiveness against coronavirus and four types of influenza virus.

The head of the Vector Center of Rospotrebnadzor Rinat Maksyutov announced the start of the development of such a vaccination. The development is carried out at the National Medical Research Center (NMIC) named after. V.A. Almazov and at the Center. Gamaleya. In January last year, the head of the Center. Gamalei Alexander Gintsburg said that such a drug could appear in the country by the end of 2022.

In the United States allowed COVID-revaccination of children from five years

In September 2021, the Ministry of Health announced the start of research on a combined vaccine, preclinical trials, according to the Minister of Health, were carried out on animals. At the end of October, RUSSIA approved the possibility of being vaccinated against coronavirus and influenza at the same time.

The number of coronavirus infections continues to decline; over the past day, 16,343 new cases of COVID-19 have been recorded in Russia. Mortality is also decreasing, 835 patients with coronavirus died per day.

Vaccination in regions of Russia December 30 Number of vaccine doses applied per 100 population of the region* first dose second dose <30 0 30-40 0 40-50 0 50-60 0 >60 0 Created with Highmaps 5.0.10Zoom in+Zoom out- * May not be equal to the proportion of the vaccinated population. The operational headquarters includes data on revaccination in the information on vaccination with the first and second dose. At the same time, he does not specify whether people who have been revaccinated once or several times are taken into account. Sources: Coronavirus Operational Headquarters, Rosstat, RBC calculations Data for Russia i